Sign up
Pharma Capital
Market: LSE
52-week High/Low: 13.50p / 0.15p
Sector: Health Care, Equipment & Services
Market Cap: 0.30M

WideCells Group PLC is a worldwide healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment.


** Click here to read a full statement from the Group CEO Joao Andrade on the momentous news that WideCells Group has been included in the DISRUPT 100 index as the 21st most disruptive firm in the world **

WideCells Group

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in WideCells Group

WideCells Group Snapshot

We are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.

WideCells Group PLC blends a unique business model with an expert team to bring promising cord blood banking and stem cell therapy from the lab to the real world of family healthcare protection.

We founded WideCells Group PLC to leverage that expertise to create a truly unique, wholly sustainable group of companies; complementing each other and all striving to positively shape the future of the industries we work in.


Welcome To WideCells Group Healthcare

Our proposition is simple: we want to help the cord blood banking industry solve their problems through innovative insurance and finance solutions.

CellPlan is the world’s first global stem cell healthcare plan, designed to revolutionise stem cell healthcare by making stem cell transplants affordable for families who require treatment for life threatening diseases.

The company is committed to provided a solution to a major problem in the cord blood banking market. Worldwide, around three million people have stored their newborn’s umbilical cord blood, which contains potentially life saving stem cells, in over 500 cord blood banks to protect their families against future illness. But future treatments, if required, can cost up hundreds of thousands of pounds meaning the majority of families will not be able to afford the treatment.

CellPlan not only gives families the opportunity to safeguard their future, by providing cover for those who store stem cells, but also includes several services to help patients obtain the right diagnosis and the most effective treatment plan.

In addition to providing medical and financial support for families requiring stem cell treatment, CellPlan also includes a unique global membership programme, called Excel, for cord blood banks.


Welcome to WideCells Group Science

We pour commitment, passion and a drive for perfection in every human tissue we bank. Our WideCells business is leading the way in the development and use of cell banking services that will help set the standard for the future.

WideCells is the most established arm of the Group, which has historically offered stem cell processing, retrieval and storage services in Spain and Portugal. The Group has been offering umbilical cord stem cells processing and storage services under its BabyCells brand in Portugal since early 2014.

The Group is in the process of establishing and licensing collection, storage and processing facilities at its laboratory at UMIC, which is designed to apply industry-leading techniques to optimise the viability and usability of stem cells, and is well positioned to capture an increasing share of the cord blood banking market in Europe, Middle-East and Africa.

Through WideCells Brasil, WideCells is also providing its services in Brazil. WideCells Brasil operates a stem cell laboratory in São Paulo, Brazil, licensed by the Brazilian regulatory authority, the Agência Naciónal de Vigilância Sanitáría (ANVISA).

As such, the company is positioned to store stem cells for individuals anywhere along the age spectrum. With this approach, the directors believe WideCells Group has the potential to grow into a global provider of stem cell services.


Wideacademy is the education and training division of the WideCells group. It aspires to advocate, develop and share thought leadership around stem cell technology, influencing the coming wave of stem cell therapies and the next generation of practitioners.

The driving principle for Wideacademy is to bring thought leadership, advocacy and education around stem cell therapies to a global audience. Many of the world’s general practitioners have not been taught about stem cell innovation and the best practice around therapies whilst at medical school. Similarly, the next generation of doctors and nurses will have little formal education in this exciting and innovative sector of medicine. Given that the insurance industry will be a key partner in facilitating a program of insurance to support this innovative medical practice, (and, ultimately, the wellbeing of their customers). Then there is an urgent case for best practice to be communicated efficiently, objectively and pragmatically, deflecting jargon, and ultimately becoming the trustworthy partner in this journey.

Peter Presland
Non-Executive Chairman
Peter has a track record of building both large and small companies through the development of corporate strategies to create shareholder value. Over his 45-year career he has held numerous chairmanships and directorships spanning a range of sectors including pharmaceutical, healthcare and insurance. He was CFO then CEO for 17 years at C E Heath PLC, a London Stock Exchange listed major international insurance group, and has held previous non-executive positions at East Kent Hospitals University Foundation NHS Trust, one of the largest Foundation Trusts in the UK, John Holman & Sons Limited, the (then) oldest independent Lloyd’s insurance broker, and Chairman at Link, the UK ATM network.


João Andrade
Chief Executive Officer
João, one of the co-founders of the WideCells business, has a strong background in marketing and international business development, and brings his considerable business experience, strategic thinking and industry specific knowledge. João has over eight years senior experience in the stem cell market, and, prior to founding WideCells, served in key roles at two European cord blood banks and service providers, with operations in several countries. With an extensive contact network and unrivalled knowledge of the stem cell industry, João is committed to creating the world’s first end-to-end stem cell service soluction, which drives change and development within this growing industry.


Lopes Gil
Chief Operating Officer
Lopes Gil is a co-founder of WideCells, and has over 25 years' experience working as an area manager in Merck KGaA and Mylan N.V. in Portugal, creating and establishing complex business operations. In addition, he has extensive business experience in international marketing, strategic planning and studies in the pharmaceutical industry. Lopes was previously Chief Finance Strategist at an European cord blood bank, where he was focused on developing its international cell banking services. He holds a degree in management from Instituto Superior Miguel Torga, and an MBA from Universidad San Pablo-CEU.


Alan Greenberg
Group Chief Business Development Officer and VP Wideacademy
Alan has a wealth of experience nurturing start-up companies predominantly in Education Technologies and Healthcare sectors globally. Alan was previously Head of Higher Education at Apple EMEA, then Apple Education Director, China. His team were responsible for building the technologies behind Podcasting and iTunes U. Though predominantly continuing the growth of Wideacademy, Alan’s responsibilities include business development strategies for the Group, designing and implementing processes to support growth.


David Bridgland
Chief Financial Officer

David studied engineering at Cambridge University and is a Chartered Accountant. He has over 20 years of business experience in a range of companies, from privately owned and venture capital backed companies to major listed companies, including Smiths Group, Autoliv and Honeywell. David's key focus is early stage businesses with innovative technologies, and he has experience in raising funding, organic business growth, acquisitions and has achieved successful trade sale exists for investors.


Prof. Peter Hollands
Chief Scientific Officer

Peter trained at Cambridge University under the supervision of Professor Sir Robert Edwards FRS, the inventor of IVF and Nobel Laureate, gaining a PhD from Cambridge University in stem cell technology. Peter held a post-doctorate position as a Senior Embryologist at the first IVF clinic in the world, Bourn Hall Clinic, and has carried out research in stem cell technology, has written numerous papers and book chapters on stem cell technology, and has been invited to lecture on stem cell technology in the Vatican, House of Lords and the Canadian Parliament. He has also been involved in clinical transplantation as Quality Manager in the Bone Marrow Transplantation Unit at Great Ormond Street Hospital for Children. Most recently, Peter was Chief Scientific Officer of Smart Cells Information Ltd., a UK cord blood bank, and Cells for Life Ltd. in Canada.


Malcolm Glaister
Non-Executive Director

Malcolm has extensive capital markets experience having held a number of management roles across a broad spectrum of leading investment and trading business. In 2012, he founded Farm Street LLP of which he is currently CEO, delivering financial advice to UK entrepreneurs and businesses, covering corporate finance, treasury debt, and asset management. Malcolm is also Founding Partner of the Eight Great Technologies Investment Fund LP, a venture capital fund focusing on investing in emerging UK tech companies. Prior to this, Malcolm was Head of Private Banking for Lloyds Bank PLC, and Head of Family Offices and a senior private banker at JP Morgan.


David Henriques
Non-Executive Director and Chairman of the Group’s Audit/Risk Committee
As an experienced corporate financier who is involved with the digitalisation of insurance products, Mr. Henriques brings a unique skill set to support the continued growth of WideCells Group. He is a co-Founder and Director of Cairn Capital Ltd (‘Cairn’), a full-service credit asset management firm, and was formerly co-Global Head of Structured Credit Products with the Royal Bank of Scotland. Prior to this, he held various senior positions in corporate finance and insurance companies. He is currently a Non-Executive Director of Azur Group Holdings Limited, an Insurance Managing Digital Agency, which partners with carriers and brokers to build, underwrite and distribute digital insurance products.


Dr Marilyn Orcharton
Non-Executive Director

A serial entrepreneur, Marilyn is a qualified dentist with a medal of Honour from the British Dental Association, and her first business was a dental practice. She co-founded Denplan Limited in 1986, which is still the UK's market leader in dental insurance, with a multi-million pound annual turnover. Marilyn sold her stake in Denplan in 1992 and founded Kite Consultants Ltd, which has researched and developed ISOPLAN, a unique business management software package for professional outlets: dentists, doctors, nursing homes and lawyers. She is a founder member of the Entrepreneurial Exchange and has been an honouree of the Leading Women Entrepreneurs. Marilyn was also a visiting surgeon at the University of Glasgow and the first woman to be a dental advisor to the Medical Defence Union and president of the Glasgow Chamber of Commerce. She also has a diploma in marketing and is a member of the Chartered Institute of Marketing.

Key shareholders as at 29th June 2018 which hold more than 3% in the Company

Shareholder Number of Ordinary Shares Share Capital (%)
João Andrade 8,388,333 6.28%
Lopes Gil 8,316,667 6.23%
Miton Group 14,764,502 11.06%
Smaller Company Capital Ltd 6,611,716 4.95%
Dominus Investments 4,311,386 3.2%
Shareholders with >3% 42,392,604 31.75%
David Bridgland 2,070,648 1.55%
Peter Hollands 166,667 0.12%
Alan Greenberg 35,714 0.03%
Peter Presland 1,666,667 1.25%
Malcolm Glaister 500,000 0.37%
David Henriques 1,333,333 1.0%
Marilyn Orcharton 324,762 0.24%
Alvaro Salas 181,663 0.14%
Shares not in Public Hands 48,672,058 36.45%
Shares in Public Hands 84,847,307 63.55%
Total Shares in Issue 133,519,365 100.0%



WideCells Group PLC
Core Technology Facility
46 Grafton Street, Manchester M13 9NT
United Kingdom

Email: [email protected]
Office Phone: +44 (0)161 920 7953

Company Secretary

David Vernon Bridgland

Registered Office

Core Technology Facility
46 Grafton Street
M13 9NT


Smaller Company Capital Limited
3rd Floor
15 Eldon Street

Shard Capital Partners LLP
23rd Floor
20 Fenchurch Street

Solicitors to the Company

Fladgate LLP
16 Great Queen Street

Auditors and Reporting Accountants

3 Hardman Street
M3 3AT

Public Relations

St Brides Partners Limited
3 St Michael’s Alley


Share Registrars Limited
Suite E, First Floor
9 Lion and Lamb Yard

View full WDC profile View Profile
View All

Columns Including WDC


Market Reports Including WDC


Executive video interviews


© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.